A glance at the literature from 2010-2018
A growing body of evidence and expert reviews suggests that we should be altering our administration regimes of beta-lactam and carbapenams to accommodate an altered volume of distribution (or RRT) status of the critically ill patient in order to more effectively reach the inhibitory concentrations of drug required to kill susceptible pathogens. Don't forget you can catch the full trials at pubmed.gov and enter the PMID within the infographic. HD FULLSCREEN HERE PDF at bottom of page
0 Comments
|
USE OF THIS WEBSITE IS SUBJECT TO AGREEING TO THIS DISCLAIMER
|